B16F10 Murine melanoma cells express interleukin-2 and a functional interleukin-2 receptor

Tumor Biology

Volumn 17, Issue 3, 1996, Pages 155-167

  García de Galdeano, Alicia ^a   Boyano, Dolores ^a   Smith Zubiaga, Isabel ^a   Cañavate, Luz ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

B16F10 melanoma; Cell proliferation; Interleukin 2 expression; Interleukin 2 receptor

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; RECOMBINANT INTERLEUKIN 2;

ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; MELANOMA B16; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029983846     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1159/000217978     Document Type: Article

References (50)

1. Smith KA: Interlcukin-2: Inception, impact, and implications. Science 1988;240:1169-1176.
2. Taniguchi T, Minarni Y: The IL-2/ IL-2 receptor system: A current overview. Cell 1993;73:5-8.
3. Tigges MA, Casey LS, Koshland ME: Mechanism of interleukin-2 signaling: Mediation of different outcomes by a single receptor and transduction pathway. Science 1989;243:781-786.
4. Henney CS, Kuribayashi K, Kern DE, Gillis S: Intcrleukin-2 augments natural killer cell activity. Nature 1981;291:335-338.
5. Malkovsky M, Loveland B, North M, Ashcrson GL, Gao L, Ward P. Fiers W: Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature 1987: 325:262-265.
6. Bcnvenistc EN, Merrill JE: Stimulation of oligodendroglial proliferation and maturation by intcrleukin-2. Nature 1986:321:610-613.
7. Frasier-Scott K, Hatzakis H, Seong D, Jones CM. Wu KK: Influence of natural and recombinant interleukin 2 on endothelial cell arachidonate metabolism. J Clin Invest 1988: 82:1877-1883.
8. Steiner G, Tschachler E, Tani M, Malck TR, Shcvach EM, Holter W, Knapp W, Wolff K, Stingl G: Interleukin 2 receptors on cultured murine epidermal Langcrhans cells. J Immunol 1986;137:155-159.
9. Boehm KD, Kelly ME, Ilan J, Ilan J: The interleukin 2 gene is expressed in the syncytiotrophoblast of the human placenta. Proc Natl Acad Sei USA 1989:86:656-660.
10. Eitan S, Zisling R, Cohen A, Belkin M, Hirschberg DL, Lotan M, Schwartz M: Identification of an interleukin 2-like substance as a factor cytotoxic to oligodendrocytes and associated with central nervous system regeneration. Proc Natl Acad Sei USA 1992:89:5442-5446.
11. Paciotti GF, Tamarkin L: Interleu-kin-2 differentially affects the proliferation of a hormone-dependent and a hormone-independent human breast cancer cell line in vitro and in vivo. Anticancer Res 1988:8:1233-1240.
12. Carloni G, Paterson H, Marell M, Augery-Bourget Y, Sahraoui J, Rubinstein E, Suarez H, Azzarone B: N-ras dependent revertant phenotype in human HT1080 fibrosarcoma cells is associated with loss of proliferation within normal tissues and expression of an adult membrane antigenic phenotype. Oncogene 1989:4:873-880.
13. Arzt E, Stelzer G, Renner U, Lange M, Müller OA, Stalla GK: Interleukin-2 and interlcukin-2 receptor expression in human corticotrophic adenoma and murine pituitary cell cultures. J Clin Invest 1992:90: 1944-1951.
14. Weidmann E, Sacchi E, Plaisance S, Heo DS, Yasuntura S, Lin W, Johnson JT. Herberman RB, Azzarone B, Whiteside TL: Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ. Cancer Res 1992:52:5963-5970.
15. Alilcchc A, Plaisance S, Han DS, Rubinstein E, Mingari C, Bellomo R, Jasmin C, Azzarone B: Human melanoma cell line M14 secretes a functional interleukin 2. Oncogene 1993;8:1791-1796.
16. Plaisance S, Rubinstein E, Alileche A, Han DS, Sahraoui Y, Mingari C, Bellomo R, Rimoldi D, Colombo MP. Jasmin C: Human melanoma cells express a functional interleu-kin-2 receptor, lnt J Cancer 1993: 55:164-170.
17. Rimoldi D, Salvi S, Hartmann F, Schreyer M, Blum S, Zografos L, Plaisance S, Azzarone B, Carrel S: Expression of IL-2 receptors in human melanoma cells. Anticancer Res 1993:13:555-564.
18. Rosenberg SA, Packard BS, Aeber-sold PM. Solomon DD, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA. Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE: Use of tumor-infiltrating lymphocytes and intcr-leukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988:319:1676-1680.
19. Bcnnicelli JL, Elias J, Kern J, Guer-ry D: Production of 1L-I activity by cultured human melanoma cells. Cancer Res 1989;49:930-935.
20. Burrows FJ, Haskard DO, Hart IR, Marshall JF, Selkirk S, Poole S, Thorpe PE: Influence of tumor-derived interleukin-1 on melanoma-endothelial cell interactions in vitro. Cancer Res 1991:51:4768-4775.
21. Colombo P, Maccalli C, Mattei S, Mclani C, Radrizzani M, Parmiani G: Expression of cytokine genes, including IL-6 in human malignant melanoma cell lines. Melanoma Res 1992;2:181-189.
22. Lu C, Kerbel RS: Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 1993; 120:1281-1288.
23. Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler H: Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994:54:3242-3247.
24. Alexander MA, Bennicelli J, Guerry D: Defective antigen presentation by human melanoma cell lines cultured from advanced but not biologically early disease. J Immunol 1989;142:4070-4078.
25. Boyano ML, Smith-Zubiaga I, Alvarez A, García de Galdeano A, Barbera-Guillem E, Canavate ML: Enhancement of la antigen expression and nonproliferating cells correlates with metastatic capacity. Pathobiology 1994:62:186-193.
26. Sambrook J, Fritsch EL, Maniatis T: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor. Cold Spring Harbor Laboratory, 1989.
27. Kawasaki ES: Amplification on RNA; in Innis MA, Gclfand DH. Sninsky JL White TI (eds): PCR Protocols: A Guide to Methods and Applications. San Diego. Academic Press, 1991. pp 21-27.
28. Kerbel S: Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Am J Pathol 1992:141:519-524.
29. Leonard WJ, Kränke M, Pfeffer NJ, Depper JM, Greene WC: Interleukin 2 receptor gene expression in normal human T lymphocytes. Proc Natl Acad Sei USA 1985;'82:6281-6285.
30. Vitte-Mony I, Goy A, Guizani L, Bertoglio JH: Cyclic AMP upregu-lates mRNA and surface expression of IL-2Ra p55 (Tac) in normal human NK cell clones. Mol Immunol 1992;29:593-600.
31. Scheibenbogen C, Keilholz U, Richter M, Andreesen R, Hunstein W: The inlcrleukin-2 receptor in human monocytes and macrophages: Regulation of expression and release of the u and ß chains (p55 and p75). Res Immunol 1992;143:33-37.
32. u: Identification of novel inter-molecular association. Cell I989;59: 837-845.
33. Takcshita T, Asao H, Ohtani K, Ishii N, Kumaki S, Tanaka N, Munakata H, Nakamura M, Sugamura K: Cloning of the y chain of the human IL-2 receptor. Science 1992: 257:379-382.
34. Herrmann F, Cannistra SA, Linde-mann A, Blohm D, Rambaldi A, Mertelsmann RH. Griffin JD: The high affinity interleukin 2 receptor: Evidence for three distinct polypeptide chains comprising the high affinity interleukin 2 receptor. J Immunol 1987;142:139-143.
35. Weil-Hillman G, Voss SD, Fisch P. Schell K, Hank JA. Sosman JA: Sugamura K, Sondel PM: Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptors and maintain the p55 (TAC) negative phenotype. Cancer Res 1990:50:2683-2691.
36. Kniep EM, Strelow I, Lohmann-Matthes ML: The monocyte interleukin-2 receptor light chain: Production of cell-associated and soluble interleukin-2 receptor by monocytes. Immunology 1992:75:299- 304.
37. Heldin CH, Betsholtz C, Claesson-Welsh L, Westcrmark B: Subversion of growth regulatory pathways in malignant transformation. Biochim BiophysActa 1987;907:219-244.
38. Cantrell DA. Smith KA: The interleukin-2 T-cell system: A new cell growth model. Science 1984:224: 1312-1316.
39. Mingari MC, Gerosa F, Carra G, Accoila RS, Moretta A, Zubler RH, Waldmann TA, Moretta L: Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature 1984;312:641-643.
40. Tsudo M, Goldman CK, Bongiovanni KF, Chan WC, Winton EF, Yagita M, Grimm EA. Waldmann TA: The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. Proc Natl Acad Sci USA 1987:84:5394-5398.
41. Rocha B, Lehuen A, Papiemik M: IL-2-dependent proliferation of thymic accessory cells. J Immunol 1988:140:1076-1080.
42. Aaronson SA: Defective antigen presentation by human melanoma cell lines cultured from advanced but not biologically early disease. Science 1991:254:1146-1153.
43. Lang RA, Burgess AW: Autocrine growth factors and tumourigcnic transformation. Immunol Today 1990;11:244-249.
44. Nicolson GL: Cancer progression and growth: Relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis. Exp Cell Res 1993:204:171-180.
45. Richmond A: The pathogenic role of growth factors in melanoma. Semin Dermatol 1991:10:246-255.
46. Shill IM. Herlyn M: Role of growth factors and their receptors in the development and progression of melanoma. J Invest Dermatol 1993:100: 196S-203S.
47. Rodeck U: Growth factor independence and growth regulatory pathways in human melanoma development. Cancer Metastasis Rev 1993: 12:219-226.
48. Keating MT, Williams LT: Autocrine stimulation of intracellular PDGF receptors in v-sis-transformed cells. Science 1988:239: 914-916.
49. Bejcck BE, Li DY, Deuel TF: Transformation by v-sii occurs by an internal autoactivation mechanism. Science 1989;245:1496-1499.
50. Dunbar CE, Browder TM, Abrams JS, Nicnhuis AW: COOH-terminal-modified interleukin-3 is retained intracellularly and stimulates autocrine growth. Science 1989;245: 1493-1496.